bioRxiv Science⌕ Search

bioRxiv · 10.1101/404400

The capsule regulatory network of Klebsiella pneumoniae defined by density-TraDISort

Abstract

Klebsiella pneumoniae infections affect infants and the immunocompromised, and the recent emergence of hypervirulent and multi-drug resistant K. pneumoniae lineages is a critical healthcare concern. Hypervirulence in K. pneumoniae is mediated by several factors, including the overproduction of extracellular capsule. However, the full details of how K. pneumoniae capsule biosynthesis is achieved or regulated are not known. We have developed a robust and sensitive procedure to identify genes influencing capsule production, density-TraDISort, which combines density gradient centrifugation with transposon-insertion sequencing. We have used this method to explore capsule regulation in two clinically-relevant Klebsiella strains; K. pneumoniae NTUH-K2044 (capsule type K1), and K. pneumoniae ATCC43816 (capsule type K2). We identified multiple genes required for full capsule production in K. pneumoniae, as well as putative suppressors of capsule in NTUH-K2044, and have validated the results of our screen with targeted knockout mutants. Further investigation of several of the K. pneumoniae capsule regulators identified - ArgR, MprA/KvrB, SlyA/KvrA and the Sap ABC transporter - revealed effects on capsule amount and architecture, serum resistance and virulence. We show that capsule production in K. pneumoniae is at the centre of a complex regulatory network involving multiple global regulators and environmental cues, and that the majority of capsule regulatory genes are located in the core genome. Overall our findings expand our understanding of how capsule is regulated in this medically-important pathogen, and provide a technology that can be easily implemented to study capsule regulation in other bacterial species.\n\nImportanceCapsule production is essential for K. pneumoniae to cause infections, but its regulation and mechanism of synthesis are not fully understood in this organism. We have developed and applied a new method for genome-wide identification of capsule regulators. Using this method, many genes that positively or negatively affect capsule production in K. pneumoniae were identified, and we use these data to propose an integrated model for capsule regulation in this species. Several of the genes and biological processes identified have not previously been linked to capsule synthesis. We also show that the methods presented here can be applied to other species of capsulated bacteria, providing the opportunity to explore and compare capsule regulatory networks in other bacterial strains and species.

Source connections

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Dorman, M. J., Feltwell, T., Goulding, D., Parkhill, J., Short, F. L.. 2018-08-31. The capsule regulatory network of Klebsiella pneumoniae defined by density-TraDISort. https://doi.org/10.1101/404400

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Lipid nanoparticle-encapsulated mRNA encoding CagW, a conserved component of the Helicobacter pylori type IV secretion system, protects mice against H. pylori challenge

Background: Roughly one person in two carries Helicobacter pylori, a pathogen classified by the World Health Organization as a group I carcinogen, and the steady loss of antibiotic efficacy has made prophylaxis an urgent rather than an optional goal. No mRNA vaccine against this organism has yet been tested in the clinic, and CagW, a conserved inner-membrane subunit of the H. pylori type IV secretion system (T4SS), has never been evaluated as an mRNA-encoded antigen. Methods: A codon-optimised construct carrying a signal peptide, the CagW coding sequence and a human IgG Fc tag was synthesised, transcribed into mRNA, encapsulated in lipid nanoparticles (LNPs) and shown to direct antigen expression in HEK293T cells. C57BL/6 mice received three intramuscular doses of CagW-Fc mRNA-LNPs (5 ug mRNA each) at 14-day intervals; animals given alum alone, luciferase mRNA-LNPs or CagW protein adsorbed to alum served as comparators. Humoral readouts (IgG, IgG1, IgG2a, IgM, IgA and secretory IgA), lymphocyte proliferation, CD4+/CD8+ subsets, intracellular IFN-{gamma}, IL-4 and IL-17A and circulating cytokines were quantified before challenge, and protection was assessed after live challenge. Results: The formulation (93.2 nm; PDI 0.13; approximately 90% encapsulation) produced CagW-specific protein in vitro. Vaccination raised high-titre CagW-specific IgG (maximal on day 42), IgM and mucosal sIgA, and drove Th1/Th2-type cellular activation (IL-2, IL-4, IL-12, IFN-{gamma} and IL-17A). After challenge, immunised animals carried markedly fewer gastric bacteria and showed lower urease activity than controls. Conclusions: CagW-Fc mRNA-LNPs are therefore a credible mRNA vaccine platform for H. pylori and warrant further preclinical development.

microbiology↗

Experimental evolution reveals temporally opposing roles for Csu pili during Acinetobacter baumannii respiratory infection

Multidrug-resistant (MDR) Acinetobacter baumannii is an opportunistic pathogen responsible for a wide range of infections, including ventilator-associated pneumonia, bloodstream infections, and urinary tract infections. Most studies investigating A. baumannii pulmonary pathogenesis rely on acute pneumonia models that use high bacterial inocula and do not recapitulate the prolonged infections observed in some patients. Recently, our laboratory developed a murine model of chronic pulmonary infection that enabled the identification of virulence factors specifically required for long-term lung persistence. To investigate how A. baumannii adapts during chronic pulmonary infection, we performed an experimental evolution study using this model. This approach revealed an unexpected role for the archaic chaperone-usher (Csu) pili in A. baumannii pathogenesis. At early time points, Csu expression reduced bacterial burdens in both acute and chronic pneumonia models, an effect associated with enhanced host inflammatory responses. In contrast, at later stages of chronic infection, Csu promoted bacterial persistence, potentially by facilitating adhesion to pulmonary epithelial cells. These opposing effects were conserved across two distinct A. baumannii clinical isolates. We also found that Csu contributes to bacterial colonization in a catheter-associated urinary tract infection (CAUTI) model in a strain-dependent manner. Together, these findings reveal an infection-stage-dependent role for Csu in A. baumannii pathogenesis, demonstrating that a bacterial surface structure can impair early colonization while promoting long-term persistence.

microbiology↗

A Vma13-targeted thiadiazole-succinimide disrupts V-ATPase dependent arginine-polyamine homeostasis to block Candida albicans escape from macrophages

Invasive candidiasis caused by Candida albicans is a life-threatening nosocomial infection with limited therapies and high morbidity and mortality among immunocompromised patients. Within host phagocytes, C. albicans catabolizes arginine to produce ammonia and fuels polyamine biosynthesis, which correlates with phagosomal alkalinization and yeast-to-hypha morphogenesis, facilitating macrophage escape and systemic dissemination. However, new antifungal strategies blocking this fungal escape remain scarce. Here, we characterize the thiadiazole-succinimide derivative ETSI, an arginine-dependent antifungal small molecule with minimal direct growth inhibition under arginine-free conditions yet robust anti-C. albicans activity in arginine-rich microenvironments mimicking the macrophage intracellular niche. Mechanistically, ETSI targets the vacuolar Vma13 to inhibit vacuolar H-ATPase (V-ATPase), dissipating vacuolar proton (H+) gradients and leading to cytoplasmic H+ retention. The accumulated cytoplasmic H+ traps intracellular ammonia and blocks its external release, while impaired vacuolar metabolite sequestration further triggers cytotoxic accumulation of arginine and polyamine metabolites. This dual metabolic perturbation suppresses phagosomal alkalinization, retains C. albicans in yeast form and blocks macrophage escape. ETSI is the first small molecule blocking C. albicans escape via disrupted Vma13/V-ATPase dependent arginine-polyamine homeostasis. This work identifies an intracellular metabolic vulnerability and establishes a niche-targeted antifungal strategy distinct from classic growth-suppressive drugs for treating invasive candidiasis.

microbiology↗